Thyroid GuidePx® is now cited in the 2025 ATA Guidelines.
This recognition highlights the growing role of molecular classifiers in papillary thyroid cancer — providing patient-specific recurrence risk to guide treatment decisions.
It’s a proud milestone for Qualisure Diagnostics and for precision oncology. And it’s just the beginning. We remain committed to generating the evidence that will continue to advance Thyroid GuidePx® and improve care for patients worldwide.